BackBrooklyn ImmunoTherapeutics Overview
Brooklyn ImmunoTherapeutics Inc

Brooklyn ImmunoTherapeutics Return on Equity

Brooklyn ImmunoTherapeutics (BTX) has a ROE of -4.91%, below the Telecommunications sector average of 10.49%.

Get informed when a big investor buys or sells

+ Follow

ROE

-4.91%

Return on Equity

-4.91%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Brooklyn ImmunoTherapeutics (BTX) FAQ

The latest ROE for BTX is -4.91%. That is below the Telecommunications sector average of 10.49%. Investors often review this figure alongside Brooklyn ImmunoTherapeutics's historical trend and sector peers before judging valuation or financial health.

Against Telecommunications companies, BTX currently prints -4.91% for ROE, while the sector average sits near 10.49%. That is roughly 146.8% below the sector mean. Large gaps often invite a closer look at Brooklyn ImmunoTherapeutics's growth, margins, and balance sheet.

Return on Equity shows how effectively Brooklyn ImmunoTherapeutics converts resources into returns. At -4.91%, BTX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BTX's ROE (-4.91%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Brooklyn ImmunoTherapeutics's ROE against similar Telecommunications names. You can also browse sector and industry screens on Stockcircle for a broader set of Telecommunications companies and their key multiples and fundamentals.